Plenary Moderator: Jerome Rossert, Vice President, Head of Clinical Renal, AstraZeneca
8:10 am Chair’s Opening Remarks: The Value Proposition of Early Identification & Intervention of Kidney Disease
What’s Next? Opportunities for Additional Drug Development & Addressing Multiple Areas with Treatment
8:30 am Interplay Between Diabetes, Heart failure & CKD: What Can we Learn from Novel Drug Development?
9:00 am Remaining Unmet Medical Need in Chronic Kidney Disease: Challenges & Opportunities for Additional Drug Development
9:30 am Panel Discussion: Demonstrating Opportunity in Renal to Support a Business Case:
10:00 am What the Extracellular Matrix Tells us – Prognostic & Pharmacodynamic Biomarkers for Kidney Fibrosis in CKD
10:15 am Speed Networking
10:45 am Morning Break & Networking
Translational Drug Development Track
Track Moderator: Julie Williams, Director/Science Lead Bioscience Rena, AstraZeneca
Track Moderator: Julie Williams, Director/Science Lead Bioscience Rena, AstraZeneca
Accessing & Interrogating Data to Inform Drug Target Discovery
11:15 am Tissue Transcriptomics to Understand Molecular Mechanisms of Progressive CKD & Mechanism-based Patient Stratification
11:45 am Next-generation Analysis of Kidney Tissue by Super-resolution Microscopy
Disease Modeling for More Predictive Translation & Mechanistic Discovery
12:00 pm Applications of Kidney Organoid Disease Models to Optimize Drug Discovery Opportunity
12:30 pm Bioengineering Technologies to Model Renal Systems
Clinical Drug Development Track
Track Moderator: Kevin Fowler, President, The Voice of the Patient
Track Moderator: Kevin Fowler, President, The Voice of the Patient
Considerations & Tools to Inform Clinical Decisions & Success
11:15 am Biomarkers as Key Drug Development Tools
11:45 am 15 minute Break
12:00 pm From Diagnostic to Therapeutic Targets
12:30 pm Renal Function Surrogates for Trial Endpoints & Clinical Decision Support: Are we Reshuffling an Old Deck or Adding New Cards to the Table?
1:00 pm Lunch Break
1:45 pm Panel Discussion: Advantages & Disadvantages of Targeting Trials to Specific Orphan Indications Versus Larger Public Health Problems
Implementing Precision Medicine in Renal Disease Studying Genetic Drivers & Targetable Mutations in Chronic Kidney Disease
Plenary Moderator: Michael Boettger, Head of Clin. Exp. CV, Translational Medicine, Bayer, Research & Development, Pharmaceuticals